RxDoctor Payments Data

Abigail Bogan, PA

Medical · Bossier City, LANPI 1174304042

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.

$3,581in general payments, 2019–2025

Across 211 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$742
  • Pfizer$620
  • Lilly USA, LLC$393
  • AstraZeneca$353
  • Novo Nordisk$276
  • Bayer$267
  • plus $930 from 15 others

What the payments were for

  • Food & beverage$3,581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,581 in reported general payments places this provider in the 80th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,852
Medicare patients
103
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$40,073
MounjaroTirzepatide24$28,394
JanuviaSitagliptin Phosphate11$13,242
XareltoRivaroxaban18$11,008
Synjardy XrEmpagliflozin/Metformin Hcl12$10,695
EntrestoSacubitril/Valsartan12$8,121
Gabapentin28$486
Cephalexin15$449
Celecoxib18$358
Losartan Potassium33$355
Olmesartan Medoxomil26$336
Atorvastatin Calcium57$331
Pantoprazole Sodium14$317
Rosuvastatin Calcium34$311
Omeprazole21$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$276$40,07339 claims
Lilly USA, LLCMounjaro$393$28,39424 claims
Boehringer IngelheimSynjardy Xr$61$10,69512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 medical providers in Louisiana.

Other medical in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →